Century Therapeutics, Inc

We’re pleased to share Greg Russotti, Ph.D., Chief Technology and Manufacturing Officer, will present at the International Society for Stem Cell Research Accelerating PSC-Derived Cell Therapies Symposium in Cambridge, MA on Dec 12. Greg will speak to new approaches to efficient and cost-effective clinical manufacturing of cell therapies in a session that explores lessons learned in product development. Learn more here: https://lnkd.in/gxsfMqBT

We’re looking forward to participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York.   - Chad Cowan, Ph.D., Chief Scientific Officer, will participate in the “State of the Art in Cell Therapy” panel discussion on Tuesday, December 2, at 12 p.m. ET.  - Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Dr. Cowan will participate in a fireside chat on Wednesday, December 3, at 10 a.m. ET.  Tune in to a live webcast of the fireside chat on the Investors page of our website at www.centurytx.com

This morning we announced CNTY-813, our first program for people living with Type 1 diabetes, and reported our Q3 2025 financial results. Highlights include:   💠 CNTY-813 IND-enabling studies to initiate by year-end 2025  💠 CNTY-308 advancing through IND-enabling studies   💠 Cash runway into 4Q 2027  Read more in the full press releases:   https://lnkd.in/e3wa6Vkg https://lnkd.in/eZ5Tch2S

Our SVP and Head of Research, G. Grant Welstead, PhD, recently represented Century Therapeutics on the “Breakthroughs in Cell and Gene Therapy” panel at the Montagna Symposium on the Biology of Skin.   Grant shared how Century’s iPSC-derived allogeneic platform is designed to deliver scalable, consistent, off-the-shelf cell therapies that help overcome key limitations of autologous approaches.   👏 Thank you, Grant, for showcasing our science and contributing to the broader dialogue shaping the future of cell and gene therapy.   #CellTherapy #GeneTherapy #iPSC #Allogeneic #MontagnaSymposium

We are pleased to announce that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics will present at the 9th Annual Chardan Genetic Medicines Conference held Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY.  A live webcast of the presentation will be available on the Investors page of our website, with a replay accessible for at least 30 days. Tune in here: https://lnkd.in/ewCnpCAj #Investors #Biotech #CellTherapy #iPSC #CenturyTherapeutics 

Century Therapeutics is pleased to announce that our webcast presentation at the H.C. Wainwright & Co., LLC 27th Annual Global Investment Conference is now available. Stream here: https://lnkd.in/ezxi5RfH Members of our management team will be available throughout the conference to connect on September 9-10, 2025, in New York, NY. We look forward to discussing our progress in advancing iPSC-derived allogeneic cell therapies for cancer and our commitment to delivering innovative treatments for patients. #CenturyTherapeutics #HCWainwright #CellTherapy #Biotech #Innovation #HCWConference

Century Therapeutics (NASDAQ: #IPSC) Announces Q2 2025 Financial Results and Business Update    Highlights include:    💠 Continued progress for autoimmune candidate, CNTY-101  💠 CNTY-308 advancing through IND-enabling studies   💠 Accelerating non-immune cell program toward drug candidacy using iPSC and Allo-Evasion™ 5.0 technology  💠 Extended cash runway into Q4 2027  💠 CEO Brent Pfeiffenberger appointed as Board Chair    Read more in the full press release: https://lnkd.in/eUGxpCcm   #InvestorUpdate #Biotech #CellTherapy #CNTY #ClinicalDevelopment #Autoimmune

This weekend, members of the Century Therapeutics team proudly joined the JM community and the Cure JM Foundation at two important events: the 15th Annual Cure JM National Family Conference and the Cure JM Foundation Walk Strong Chicago.   At the Family Conference, our Executive Medical Director, Anne M. Stevens, M.D., Ph.D., participated in two impactful panels — including The Future of Therapy: Emerging Treatments and Protocols in Myositis — where she shared insights on advancing treatment options for JM.   Meanwhile, Poulomee Das, represented Century at the Walk Strong event in Chicago, walking in solidarity with families and advocates committed to making a difference.   We’re honored to support Cure JM and help drive progress in the fight against juvenile myositis.   #CureJM #JuvenileMyositis #RareDisease #PatientFocused #CenturyTherapeutics  

What an inspiring week at #EULAR2025! We’re proud to have shared our latest research on iPSC-derived cell therapies, including two key presentations that highlight our commitment to advancing treatment options for autoimmune diseases.    Thank you to the EULAR - European Alliance of Associations for Rheumatology community for the opportunity to connect with leading clinicians, researchers, and advocates who share our vision for innovative, patient-centered care.   And thank you to Hongxia Zhang, Ph.D. and Jonathan Kurtz, Ph.D. for representing Century Therapeutics at the event!    Missed our sessions? Check out our presentations and scientific progress by visiting us here: https://lnkd.in/eUTRWCiz    #CellTherapy #AutoimmuneDisease #Immunotherapy #EULAR2025 #CenturyTherapeutics

June is Scleroderma Awareness Month—a time to raise awareness and stand alongside those affected by this complex autoimmune disease.   At Century Therapeutics, we’re leveraging the power of iPSC-derived cell therapies to tackle challenging diseases like #scleroderma, where unmet needs remain high.    We’re looking forward to attending the National Scleroderma Foundation's annual National Scleroderma Conference held July 18-20 in St. Louis, Missouri. We’re eager to connect with patients, caregivers, and researchers to exchange knowledge and explore how novel immunotherapies may help shape the future of #scleroderma care.   #SclerodermaAwarenessMonth #CellTherapy #AutoimmuneDisease #NationalSclerodermaConference